1987
DOI: 10.1016/s0140-6736(87)91214-1
|View full text |Cite
|
Sign up to set email alerts
|

Lfa-1, Lfa-3, and Icam-1 Expression in Burkitt's Lymphoma

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

1
13
0
2

Year Published

1990
1990
2003
2003

Publication Types

Select...
7

Relationship

1
6

Authors

Journals

citations
Cited by 47 publications
(16 citation statements)
references
References 6 publications
1
13
0
2
Order By: Relevance
“…The serum levels of sICAM-1 have been previously shown to be elevated in many malignancies including lung, breast, pancreas and bladder cancers and correlated with the stage of the disease [7][8][9][10][11][12]. In the present study, our results have confirmed that the serum levels of sICAM-1 are higher in patients having TCC of the bladder than healthy controls.…”
Section: Discussionsupporting
confidence: 88%
See 2 more Smart Citations
“…The serum levels of sICAM-1 have been previously shown to be elevated in many malignancies including lung, breast, pancreas and bladder cancers and correlated with the stage of the disease [7][8][9][10][11][12]. In the present study, our results have confirmed that the serum levels of sICAM-1 are higher in patients having TCC of the bladder than healthy controls.…”
Section: Discussionsupporting
confidence: 88%
“…ICAM-1, which is one of the ligands of LFA-1, has been shown to play an important role in various mechanisms such as cell-mediated immune response, inflammation, tumor progression and metastasis. ICAM-1 is expressed not only on hematopoietic cells but also non-hematopoietic cells such as endothelial cells and dermal fibroblasts [13] as well as on malignant cells such as those of lymphomas [7,14,15], melanomas [8], and certain kinds of carcinoma [16,17].…”
Section: Discussionmentioning
confidence: 99%
See 1 more Smart Citation
“…EBV-transformed B cells were used including four different sources of B cells: (a) EBV-transformed B cell lines; (b) B cells derived from a Burkitt lymphoma (BL2) which have been shown to poorly express the LFA-1, LFA-3 and ICAM-1 membrane molecules [18,191; (c) EBV-transformed B cell lines from immunodeficient patients with an inherited deficiency in HLA class I1 molecule expression [20,21] as well as (d) mutant HLA class 11-B cells RJ225 produced by Accolla et al [22].…”
Section: Cellsmentioning
confidence: 99%
“…ICAM-1 is constitutively expressed on a variety of inflammatory and immune effector cells and in structural cells, such as: endothelial cells, fibroblasts, and epithelial cells [3]. In addition, ICAM-1 has been detected on the surface of a variety of primary tumours and tumour cell lines, including lymphomas [4], melanomas [5], renal [6], pancreatic [7], bladder [8] and lung carcinomas [9]. Because LFA-1 is expressed on mononuclear phagocytes, cytotoxic T-cells, natural-killer (NK), and lymphokine-activated killer (LAK) cells [1], the expression of ICAM-1 by tumour cells may be involved in the regulation of their susceptibility to cytotoxic activity of autologous and allogeneic defensive cells.…”
mentioning
confidence: 99%